Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 53
Filter
3.
Heart Lung Circ ; 31(2): 216-223, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34210615

ABSTRACT

AIM: Atrial fibrillation/flutter (AF/AFL) is associated with high rates of emergency department (ED) visits and acute hospitalisation. A recently established multidisciplinary acute AF treatment pathway seeks to avoid hospital admissions by early discharge of haemodynamically stable, low risk patients from the ED with next-working-day return to a ward-based AF clinic for further assessment. We conducted a preliminary analysis of the clinical outcomes of this pathway. METHODS: We retrospectively reviewed clinical records of all patients assessed at the AF clinic at Christchurch Hospital, New Zealand, over a 12-month period. Data related to presentation, patient characteristics, treatment, and 12-month outcomes were analysed. RESULTS: A total of 143 patients (median age 65, interquartile range: 57-74 years, 59% male, 87% European) were assessed. Of these, 87 (60.8%) presented with their first episode of AF/AFL. Spontaneous cardioversion occurred in 41% at ED discharge, and this increased to 73% at AF clinic review. Electrical cardioversion was subsequently performed in 16 patients (11.2%), and 16 (11.2%) ultimately required hospital admission (eight to facilitate electrical cardioversion). At a median of 1 day, 83.9% were discharged from the AF clinic in sinus rhythm. During 12-month follow-up, there were 25 AF-related hospitalisations (20 patients, 14%) and one patient underwent electrical cardioversion; additionally, one patient had had a stroke and eight had bleeding complications giving a combined outcome rate of 6.3%. CONCLUSION: Utilising a rate-control strategy with ED discharge and early return to a dedicated AF clinic can safely prevent the majority of hospitalisations, avert unnecessary procedures, and facilitate longitudinal care.


Subject(s)
Atrial Fibrillation , Atrial Flutter , Aged , Atrial Fibrillation/diagnosis , Atrial Fibrillation/epidemiology , Atrial Fibrillation/therapy , Electric Countershock , Emergency Service, Hospital , Female , Follow-Up Studies , Humans , Male , Retrospective Studies , Treatment Outcome
4.
EJIFCC ; 32(1): 27-40, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33753972

ABSTRACT

The COVID-19 pandemic raised major concerns relating to hospital capacity and cross-infection patients and staff in the Emergency Department (ED) of a metropolitan hospital servicing a population of ~500,000. We determined to reduce length of stay and admissions in patients presenting with symptoms of possible myocardial infarction; the most common presentation group. After establishing stakeholder consensus, the existing accelerated diagnostic pathway (ADP) based on the ED Assessment of Chest-pain Score (EDACS), electrocardiogram, and troponin measurements with a high-sensitivity assay (hs-cTn) on presentation and two hours later (EDACS-ADP) was modified to stream patients following an initial troponin measure as follows: (i) to a very-low risk group who could be discharged home without follow-up or further testing, and (ii) to a low-risk group who could be discharged with next-day follow-up community troponin testing. Simulations were run in an extensive research database to determine appropriate hs-cTnI and EDACS thresholds for risk classification. This COVID-ADP was developed in ~2-weeks and was implemented in the ED within a further 3-weeks. A comparison of all chest pain presentations for the 3 months prior to implementation of the COVID-ADP to 3 months following implementation showed that there was a 64.7% increase in patients having only one troponin test in the ED, a 30-minute reduction of mean length of stay of people discharged home from the ED, and a 24.3% reduction in hospital admissions of patients ultimately diagnosed with non-cardiac chest pain.

7.
Heart Lung Circ ; 24(6): 551-6, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25637940

ABSTRACT

BACKGROUND: Increasingly frail patients are being to be referred for invasive cardiac interventions and cardiac surgery. We aimed to evaluate the utility of a quick clinical assessment of frailty against a validated frailty assessment tool in an acute cardiology setting. METHODS: Forty-seven cardiology in-patients ≥70 years were recruited in this prospective study. All patients were first assessed by a senior cardiology registrar as either not-frail or frail. This was based on general observation and brief discussions. Following this, patients were administered the Reported Edmonton Frail Scale (REFS) questionnaire. After a registrar assessment, the foot-of-the bed frailty assessment was independently repeated by one or two consultant cardiologists. RESULTS: None of the three clinicians showed satisfactory similarity to the REFS score. When the two consultants were compared with the registrar, and with each other, the Cohen's kappa was only above 0.7 for the comparison between Consultant 1 and the registrar. Consultant 1 and the registrar were also significantly more likely to disagree at higher REFS score with a mean REFS score of 8.8. CONCLUSION: A quick foot-of-the-bed clinical assessment is not a reliable way to determine frailty.


Subject(s)
Activities of Daily Living , Cardiac Surgical Procedures/methods , Disability Evaluation , Frail Elderly , Geriatric Assessment/methods , Aged , Aged, 80 and over , Cardiac Surgical Procedures/mortality , Cognition Disorders/diagnosis , Cognition Disorders/epidemiology , Cohort Studies , Female , Humans , Male , New Zealand , Nutritional Status , Observer Variation , Prospective Studies , Reproducibility of Results , Risk Assessment , Severity of Illness Index , Statistics, Nonparametric , Surveys and Questionnaires , Treatment Outcome
8.
N Z Med J ; 127(1402): 88-96, 2014 Sep 12.
Article in English | MEDLINE | ID: mdl-25228424

ABSTRACT

INTRODUCTION: Adults with congenital heart disease (CHD) frequently have cardiac arrhythmias, many of which are best treated with radiofrequency ablation (RFA). We present our experience in this group. METHODS: Retrospective chart based review of diagnosis, arrhythmia type, results of cardiac electrophysiological assessment, and procedural and long-term clinical success of radiofrequency ablation. RESULTS: Forty-five patients were identified with CHD and arrhythmias undergoing RFA; including surgically repaired atrial septal defects (21), Ebstein's anomaly (12), repaired transposition of the great arteries (3), repaired Tetralogy of Fallot (4), repaired ventricular septal defect (3), repaired coarctation (1) and unrepaired anomalous pulmonary venous anatomy (1). Arrhythmias were atrial flutter (24), atrial fibrillation (1), atrial tachycardia (3), atrioventricular nodal re-entrant tachycardia (5), and atrioventricular re-entrant tachycardia (12). Procedural success was ultimately obtained in 36 patients, with 6 having unsuccessful ablation and 3 an undetermined result. Twelve patients required a repeat procedure. One patient required a third procedure and had insertion of permanent pacemaker and atrioventricular nodal ablation. With follow-up (range 2-264 months) 31 patients (69%) remained in sinus rhythm, 9 have developed atrial fibrillation, 3 are in atrial flutter or atrial tachycardia, 1 patient reports ongoing palpitations with no documented arrhythmia and 1 patient has died. Procedural complications were major venous access bleeding (2), transient heart block during slow pathway ablation with late complete heart block (1). CONCLUSIONS: The majority of arrhythmias in adult patients with congenital heart defects can be successfully treated with radiofrequency ablation at a relatively low risk.


Subject(s)
Arrhythmias, Cardiac/surgery , Catheter Ablation , Electrocardiography , Heart Defects, Congenital/complications , Adolescent , Adult , Aged , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/etiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , New Zealand , Retrospective Studies , Treatment Outcome , Young Adult
9.
Congest Heart Fail ; 19(3): 135-42, 2013.
Article in English | MEDLINE | ID: mdl-23279139

ABSTRACT

Many proven heart failure (HF) therapies decrease N-terminal pro B-type natriuretic peptide (NT-proBNP) values over time, yet some patients have an NT-proBNP >1000 pg/mL following treatment, which is associated with poor outcomes. A total of 151 patients with left ventricular systolic dysfunction were treated with aggressive HF therapy in the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Clinical characteristics and NT-proBNP were measured at each visit during 10 months. In this post hoc analysis, biomarker nonresponse was defined as an NT-proBNP >1000 pg/mL and its relationship with echocardiographic and clinical characteristics and outcomes were explored. A risk model predictive of nonresponse was derived and externally validated. A rising NT-proBNP over time was associated with increased cardiovascular event rates while a decreasing NT-proBNP was associated with better clinical outcomes (58.2% vs 27.6%, P=.001). A higher percentage of time in biomarker response was associated with lower event rates (P<.001). Importantly, responders showed improved left ventricular remodeling parameters (all P<.001), while nonresponders did not. A risk model for predicting nonresponse had a C statistic of 0.82 (P<.001) and predicted outcomes well. Using data from the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) cohort, the risk score was validated for its ability to predict nonresponse (C statistic 0.73, P<.001). Serial changes in NT-proBNP inform risk for adverse outcome and are associated with prognostically meaningful metrics. Prediction of future NT-proBNP nonresponse to HF therapy is possible.


Subject(s)
Heart Failure/therapy , Natriuretic Peptide, Brain/blood , Outpatients , Patient Readmission/trends , Peptide Fragments/blood , Ventricular Function, Left , Aged , Biomarkers/blood , Echocardiography , Female , Follow-Up Studies , Heart Failure/blood , Heart Failure/mortality , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Protein Precursors , Survival Rate/trends , United States/epidemiology
10.
N Z Med J ; 125(1363): 81-3, 2012 Oct 12.
Article in English | MEDLINE | ID: mdl-23159905

ABSTRACT

Right heart thrombi are unusual complications of pulmonary embolism that are associated with a high early mortality. We present a case and transoesophageal echocardiography of a 65-year-old man who presented with pulmonary embolism, following routine knee replacement and was found to have a type A right heart thrombus. Despite the increased risk associated with this presentation, treatment with heparin alone was successful.


Subject(s)
Arthroplasty, Replacement, Knee/adverse effects , Atrial Fibrillation/complications , Heparin/administration & dosage , Postoperative Complications , Pulmonary Embolism , Warfarin/administration & dosage , Acute Disease , Aged , Angiography/methods , Anticoagulants/administration & dosage , Atrial Fibrillation/diagnosis , Echocardiography, Transesophageal , Electrocardiography , Heart Atria/diagnostic imaging , Heart Atria/physiopathology , Humans , Male , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Postoperative Complications/physiopathology , Pulmonary Embolism/diagnosis , Pulmonary Embolism/drug therapy , Pulmonary Embolism/etiology , Pulmonary Embolism/physiopathology , Thrombosis/complications , Thrombosis/diagnosis , Tomography, X-Ray Computed/methods , Treatment Outcome
11.
N Z Med J ; 124(1343): 48-56, 2011 Sep 23.
Article in English | MEDLINE | ID: mdl-21964013

ABSTRACT

BACKGROUND: There is little recent information regarding outcome and its determinants following cardioversion (CV) for atrial fibrillation (AF) or flutter. This study aims to help improve prediction of cardiac rhythm outcome following CV for AF. METHODS: Cardiac rhythm at 6 weeks and 12 months was documented following elective (EC; n=496) or immediate (IC; n=52) cardioversion for AF or atrial flutter in a single referral centre. RESULTS: 65 and 58% of IC patients remained in sinus rhythm (SR) 6 weeks and 1 year after CV (respectively) compared with 43% and 30% in EC patients (P<0.001). Independent positive predictors of SR 6 weeks after cardioversion included amiodarone therapy (OR 2.04 [1.28-3.33], P<0.01) and atrial flutter (OR 1.85 [1.09-3.13], P<0.05). Negative predictors included the need for >1 shock to achieve SR (OR 1.61 [1.12-2.37], P=0.011) and arrhythmia duration, (OR 0.96 [0.95-0.97], P<0.001). At 1 year, amiodarone, duration of arrhythmia and the need for >1 shock remained independent predictors of rhythm. CONCLUSIONS: The number of shocks required to achieve SR is a newly demonstrated independent predictor of rhythm outcome after elective CV.


Subject(s)
Atrial Fibrillation/therapy , Electric Countershock/methods , Aged , Amiodarone/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Anticoagulants/therapeutic use , Atrial Fibrillation/mortality , Atrial Fibrillation/physiopathology , Atrial Flutter/mortality , Atrial Flutter/physiopathology , Atrial Flutter/therapy , Chi-Square Distribution , Electrocardiography , Female , Humans , Logistic Models , Male , Middle Aged , Predictive Value of Tests , Statistics, Nonparametric , Treatment Outcome
12.
Ann Clin Biochem ; 48(Pt 3): 241-8, 2011 May.
Article in English | MEDLINE | ID: mdl-21441390

ABSTRACT

BACKGROUND: Current guidelines define acute myocardial infarction (AMI) by the rise and/or fall of cardiac troponin with ≥1 value above the 99th percentile. Past troponin assays have been unreliable at the lower end of the range. Highly sensitive assays have therefore been developed to increase the clinical sensitivity for detection of myocardial injury. METHODS: Three hundred and thirty-two patients with chest pain suggestive of AMI were prospectively recruited between November 2006 and April 2007. Serial blood samples were analysed to compare Roche Elecsys high sensitivity troponin T (hsTnT), Abbott Architect troponin I 3rd generation (TnI 3) and Roche Elecsys troponin T (TnT) for the diagnosis of AMI. RESULTS: One hundred and ten (33.1%) patients were diagnosed with AMI. Test performance for the diagnosis of AMI, as quantified by receiver operating characteristic area under the curve (95% confidence intervals) for baseline/follow-up troponins were as follows: hsTnT 0.90 (0.87-0.94)/0.94 (0.91-0.97), TnI 3 0.88 (0.84-0.92)/0.93 (0.90-0.96) and TnT 0.80 (0.74-0.85)/0.89 (0.85-0.94). hsTnT was superior to TnT (P < 0.001/0.013 at baseline/follow-up) but equivalent to TnI 3. For patients with a final diagnosis of AMI, baseline troponins were raised in more patients for hsTnT (83.6%) than TnI 3 (74.5%) and TnT (62.7%). A delta troponin of ≥20% increased the specificity of hsTnT from 80.6% to 93.7% but reduced sensitivity from 90.9% to 71.8%. CONCLUSION: hsTnT was superior to TnT but equivalent to TnI 3 for the diagnosis of AMI. Serial troponin measurement increased test performance. hsTnT was the most likely to be raised at baseline in those with AMI. A delta troponin increases specificity but reduces sensitivity.


Subject(s)
Emergency Medical Services/methods , Myocardial Infarction/blood , Myocardial Infarction/diagnosis , Troponin I/blood , Troponin T/blood , Aged , Angina, Unstable/complications , Early Diagnosis , Female , Humans , Male , Middle Aged , Myocardial Infarction/complications , ROC Curve , Sensitivity and Specificity , Time Factors
13.
Eur Heart J ; 31(18): 2216-22, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20513730

ABSTRACT

AIMS: Left ventricular (LV) hypertrophy and abnormal non-invasive measures of LV diastolic function are common in patients with severe aortic stenosis (AS) but their prognostic importance is uncertain. This study aimed to determine whether tissue Doppler measures of LV systolic and/or diastolic function or echocardiographic LV hypertrophy are useful for risk stratifying asymptomatic patients with severe calcific AS. METHODS AND RESULTS: One hundred and eighty-three initially asymptomatic patients with moderate or severe AS (valve area mean 0.96 ± SD 0.3 cm(2)) and a normal LV ejection fraction were followed for median 31 (IQR 14-40) months. Peak systolic (S') and diastolic (E') mitral annular velocities and LV mass were measured by echocardiography at baseline and during follow-up. During follow-up 106 (58%) patients suffered symptomatic deterioration, including three sudden deaths and one resuscitated cardiac arrest. Peak aortic velocity (for 0.5 m/s increase HR = 1.43, 95% CI 1.25, 1.64, P < 0.0001) and aortic valve area (-0.1 cm(2)/m(2) HR = 1.23, 95% CI 1.12, 1.35, P = 0.004) at baseline were most strongly associated with symptomatic deterioration. After peak aortic velocity adjustment neither LV mass index nor any measure of LV systolic or diastolic function was associated with symptomatic deterioration (P > 0.2 for all). CONCLUSION: In patients with calcific AS who have a normal LV ejection fraction the severity of stenosis is the most important correlate of symptomatic deterioration. Tissue Doppler measures of LV systolic and diastolic function and LV mass provide limited predictive information after accounting for the severity of stenosis.


Subject(s)
Aortic Valve Stenosis/diagnostic imaging , Hypertrophy, Left Ventricular/diagnostic imaging , Ventricular Dysfunction, Left/diagnostic imaging , Aged , Aortic Valve Stenosis/physiopathology , Diastole , Echocardiography, Doppler, Color , Female , Humans , Hypertrophy, Left Ventricular/physiopathology , Kaplan-Meier Estimate , Male , Prognosis , Systole , Ventricular Dysfunction, Left/physiopathology
14.
Biomarkers ; 15(4): 307-14, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20370326

ABSTRACT

BACKGROUND: The prognostic value of the New York Heart Association classification (NYHAC) in acutely decompensated heart failure (ADHF) is unknown. OBJECTIVES: We sought to determine the relative value of NYHAC among patients with concomitantly measured amino-terminal pro-B type natriuretic peptide (NT-proBNP) at presentation with ADHF. MATERIALS AND METHODS: NYHAC was determined for 720 patients with ADHF and 1-year mortality status was examined. Cox-proportional hazards analysis compared the prognostic accuracy of NYHAC with other ADHF risk measures. RESULTS: NYHAC had a significant univariate association with 1-year mortality status (HR 1.41, 95% confidence interval (CI) 1.03-1.94; p = 0.03) but was not a significant predictor of death in a multivariable model that included NT-proBNP (HR 2.14; 95% CI 1.65-2.81, p < 0.001). CONCLUSIONS: In contrast to objective measures such as NT-proBNP, the NYHAC appears to provide limited prognostic information among individuals with ADHF.


Subject(s)
Heart Failure/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Acute Disease , Aged , Aged, 80 and over , Female , Heart Failure/classification , Heart Failure/mortality , Humans , Male , Middle Aged , New York , Patient Selection , Predictive Value of Tests , Ventricular Function, Left
15.
Biochim Biophys Acta ; 1792(12): 1175-84, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19782130

ABSTRACT

The heart adapts to an increased workload through the activation of a hypertrophic response within the cardiac ventricles. This response is characterized by both an increase in the size of the individual cardiomyocytes and an induction of a panel of genes normally expressed in the embryonic and neonatal ventricle, such as atrial natriuretic peptide (ANP). ANP and brain natriuretic peptide (BNP) exert their biological actions through activation of the natriuretic peptide receptor-1 (Npr1). The current study examined mice lacking Npr1 (Npr1(-/-)) activity and investigated the effects of the absence of Npr1 signaling during cardiac development on embryo viability, cardiac structure and gene and protein expression. Npr1(-/-)embryos were collected at embryonic day (ED) 12.5, 15.5 and neonatal day 1 (ND 1). Npr1(-/-)embryos occurred at the expected Mendelian frequency at ED 12.5, but knockout numbers were significantly decreased at ED 15.5 and ND 1. There was no indication of cardiac structural abnormalities in surviving embryos. However, Npr1(-/-)embryos exhibited cardiac enlargement (without fibrosis) from ED 15.5 as well as significantly increased ANP mRNA and protein expression compared to wild-type (WT) mice, but no concomitant increase in expression of the hypertrophy-related transcription factors, Mef2A, Mef2C, GATA-4, GATA-6 or serum response factor (SRF). However, there was a significant decrease in Connexin-43 (Cx43) gene and protein expression at mid-gestation in Npr1(-/-)embryos. Our findings suggest that the mechanism by which natriuretic peptide signaling influences cardiac development in Npr1(-/-) mice is distinct from that seen during the development of pathological cardiac hypertrophy and fibrosis. The decreased viability of Npr1(-/-)embryos may result from a combination of cardiomegaly and dysregulated Cx43 protein affecting cardiac contractility.


Subject(s)
Cardiomegaly/mortality , Cardiomegaly/pathology , Embryo, Mammalian/cytology , Heart/embryology , Receptors, Atrial Natriuretic Factor/physiology , Animals , Atrial Natriuretic Factor/genetics , Atrial Natriuretic Factor/metabolism , Blood Pressure , Blotting, Western , Cardiomegaly/metabolism , Connexin 43/metabolism , Embryo, Mammalian/metabolism , Female , Gene Expression Regulation, Developmental , Heart/physiology , Immunoenzyme Techniques , Male , Mice , Mice, Knockout , Natriuretic Peptide, Brain/genetics , Natriuretic Peptide, Brain/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Transcription Factors/genetics , Transcription Factors/metabolism
16.
J Infect ; 59(6): 387-93, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19766136

ABSTRACT

OBJECTIVES: To describe the use and outcomes of outpatient antimicrobial therapy (OPAT) for infective endocarditis (IE) within the Canterbury region of New Zealand over an 8 year period. METHODS: All cases of IE admitted to Christchurch Hospital were reviewed. Prospectively collected data from our OPAT service's database and retrospective data from case notes were analysed. RESULTS: There were 213 episodes of IE meeting modified Duke Criteria over this time. Patients received OPAT in 100 episodes. Viridans streptococci were the infecting organism in 34, Staphylococcus aureus in 27, and enterococci in 10. Adverse events were encountered in 27 episodes. Of these, 24 were related to intravenous lines, infusion devices or adverse drug reactions which resolved with change of treatment. There were 3 serious adverse events which were likely to have occurred in hospital. During 12-month follow-up there were 5 further episodes of IE and 2 deaths unlikely to be directly related to the episode of IE. CONCLUSIONS: Despite significant co-morbidities and complications, nearly half of all patients with IE, including those with disease due to S. aureus and enterococci, successfully completed their treatment as outpatients. Continuous infusion devices were successfully used in 32 patients, including 22 with disease due to S. aureus.


Subject(s)
Ambulatory Care , Anti-Bacterial Agents/administration & dosage , Endocarditis, Bacterial/drug therapy , Infusion Pumps , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/mortality , Female , Humans , Infusions, Intravenous , Male , Middle Aged , New Zealand , Treatment Outcome , Young Adult
17.
J Am Coll Cardiol ; 55(1): 53-60, 2009 Dec 29.
Article in English | MEDLINE | ID: mdl-20117364

ABSTRACT

OBJECTIVES: The purpose of this study was to compare the effects of N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided therapy with those of intensive clinical management and with usual care (UC) on clinical outcomes in chronic symptomatic heart failure. BACKGROUND: Initial trial results suggest titration of therapy guided by serial plasma B-type natriuretic peptide levels improves outcomes in patients with chronic heart failure, but the concept has not received widespread acceptance. Accordingly, we conducted a longer-term study comparing the effects of NT-proBNP-guided therapy with those of intensive clinical management and with UC of patients with heart failure. METHODS: Three hundred sixty-four patients admitted to a single hospital with heart failure were randomly allocated 1:1:1 (stratified by age) to therapy guided by NT-proBNP levels or by intensive clinical management, or according to UC. Treatment strategies were applied for 2 years with follow-up to 3 years. RESULTS: One-year mortality was less in both the hormone- (9.1%) and clinically-guided (9.1%) groups compared with UC (18.9%; p = 0.03). Three-year mortality was selectively reduced in patients

Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Diuretics/administration & dosage , Heart Failure/drug therapy , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Adult , Age Factors , Aged , Aged, 80 and over , Female , Heart Failure/blood , Heart Failure/mortality , Humans , Male , Middle Aged , New Zealand/epidemiology , Patient Readmission/statistics & numerical data
18.
Eur Heart J ; 28(21): 2589-97, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17720993

ABSTRACT

AIMS: To document the haemodynamic, neurohormonal, and renal responses to Urocortin 2 (UCN2) infused in human heart failure (HF). METHODS AND RESULTS: Eight male patients with HF [left ventricular ejection fraction (LVEF) < 40%, NYHA class II-III] received placebo and 25 [low dose (LD)] and 100 microg [high dose (HD)] of UCN2 intravenously over 1 h in a single-blind, placebo-controlled, dose-escalation design. UCN2 increased cardiac output (CO) (mean peak increments +/- SEM; placebo 0.3 +/- 0.1; LD 1.0 +/- 0.3; HD 2.0 +/- 0.2 L/min; P < 0.001) and LVEF (0.0 +/- 1.5; LD 5.9 +/- 2.1; HD 14.1 +/- 2.7%; P = 0.001) and decreased mean arterial pressure (placebo 6.7 +/- 1.3; LD 11.4 +/- 1.7; HD 19.4 +/- 3.3 mmHg; P = 0.001), systemic vascular resistance (SVR) (placebo 104 +/- 37; LD 281 +/- 64; HD 476 +/- 79 dynes s/cm(5); P < 0.003), and cardiac work (CW) (placebo 48 +/- 12; LD 66 +/- 22; HD 94 +/- 13 mmHg/L/min; P < 0.001). No significant effect on vasoconstrictor/volume-retaining neurohormones was noted. UCN2 decreased urinary volume (P = 0.035) but not creatinine excretion (P = 0.962). CONCLUSION: Intravenous UCN2 in HF induced increases in CO and LVEF with falls in SVR and CW. No hormone response occurred. The role of UCN2 in circulatory regulation and its potential therapeutic application in heart disease warrant further investigation.


Subject(s)
Cardiotonic Agents/pharmacology , Heart Failure/drug therapy , Urocortins/pharmacology , Adult , Aged , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/pharmacokinetics , Dose-Response Relationship, Drug , Heart Failure/physiopathology , Hemodynamics/drug effects , Humans , Kidney/drug effects , Male , Middle Aged , Single-Blind Method , Urocortins/administration & dosage , Urocortins/pharmacokinetics
19.
Clin Chim Acta ; 381(2): 145-50, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17445789

ABSTRACT

BACKGROUND: Hemoglobin and amino-terminal pro-brain natriuretic peptide (NT-proBNP) are both independent predictors of mortality in patients with chronic HF. Their combined predictive power for mortality in the setting of acute HF is uncertain. METHODS: In an international prospective cohort design, we evaluated the relationships between hemoglobin, NT-proBNP, and 60-day mortality in 690 patients with acute HF. RESULTS: The median hemoglobin for the entire cohort was 13.0 g/dL (interquartile range 11.6-14.3). The WHO criterion for anemia was met by 44% (n=305). The 60-day mortality rate for anemic patients was 16.4% vs. 8.8% in non-anemic patients (p<0.001). Anemia was an independent predictor of short-term mortality (OR=1.72, 95% CI=1.05-2.80, p=0.03), as was a NT-proBNP concentration >5180 pg/mL (OR=2.32, 95% CI=1.36-3.94 p=0.002). Consideration of four risk groups: not anemic/low NT-proBNP (reference group, n=220), anemic/low NT-proBNP (n=152), not anemic/high NT-proBNP (n=165), and anemic/high NT-proBNP (n=153) revealed respective 60-day mortality rates of 5.0% (referent), 9.2% (OR=1.93, 95% CI=0.85-4.36; p=0.12), 13.9% (OR=3.07, 95% CI=1.45-6.50, p=0.003), and 23.5% (OR=5.84, 95% CI=2.87-11.89, p<0.001). CONCLUSIONS: Anemia was common in this cohort of subjects with acute HF and was related to adverse short-term outcome. Integrated use of hemoglobin and NT-proBNP measurements provides powerful additive information and is superior to the use of either in isolation.


Subject(s)
Heart Failure/diagnosis , Heart Failure/mortality , Hemoglobins/analysis , Natriuretic Peptide, Brain/analysis , Peptide Fragments/analysis , Acute Disease , Aged , Anemia/diagnosis , Anemia/etiology , Anemia/mortality , Biomarkers , Data Interpretation, Statistical , Endpoint Determination , Female , Humans , Male , Predictive Value of Tests , Survival Analysis
20.
Arch Intern Med ; 167(4): 400-7, 2007 Feb 26.
Article in English | MEDLINE | ID: mdl-17325303

ABSTRACT

BACKGROUND: Amino (N)-terminal pro-brain natriuretic peptide (NT-proBNP) testing is useful for diagnostic and prognostic evaluation in patients with dyspnea. An inverse relationship between body mass index (BMI); (calculated as weight in kilograms divided by height in meters squared) and NT-proBNP concentrations has been described. METHODS: One thousand one hundred three patients presenting to the emergency department with acute dyspnea underwent analysis. Patients were classified into the following 3 BMI categories: lean (<25.0), overweight (25.0-29.9), and obese (>/=30.0). RESULTS: The NT-proBNP concentrations in the overweight and obese groups were significantly lower than in the lean patients, regardless of the presence of acute heart failure (P<.001). The positive likelihood ratio for an NT-proBNP-based diagnosis of acute heart failure was 5.3 for a BMI lower than 25.0, 13.3 for a BMI of 25.0 to 29.9, and 7.5 for a BMI of 30.0 or higher. A cut point of 300 ng/L had very low negative likelihood ratios in all 3 BMI categories (0.02, 0.03, and 0.08, respectively). Among decedents, the NT-proBNP concentrations were lower in the overweight and obese patients compared with the lean subjects (P<.001). Nonetheless, a single cut point of 986 ng/L strongly predicted 1-year mortality across the 3 BMI strata, regardless of the presence of acute heart failure (hazard ratios, 2.22, 3.06, and 3.69 for BMIs of <25.0, 25.0-29.9, and >/=30.0, respectively; all P<.004); the risk associated with a high NT-proBNP concentration was detected early and was sustained to a year after baseline in all 3 BMI strata (all P<.001). CONCLUSIONS: In patients with and without acute heart failure, the NT-proBNP concentrations are relatively lower in overweight and obese patients with acute dyspnea. Despite this, the NT-proBNP concentration retains its diagnostic and prognostic capacity across all BMI categories.


Subject(s)
Body Mass Index , Dyspnea/blood , Dyspnea/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Acute Disease , Aged , Biomarkers/blood , Diagnosis, Differential , Dyspnea/etiology , Female , Follow-Up Studies , Heart Failure/blood , Heart Failure/complications , Humans , Male , Middle Aged , Obesity/blood , Obesity/complications , Prognosis , Protein Precursors , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...